Gladius Capital Management LP Lyell Immunopharma, Inc. Transaction History

Gladius Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Dec 18, 2023	BUY	$1.89 - $3.86 $13,146 - $26,850	6,956 New	6,956 $22,000
Q2 2023 Aug 08, 2023	SELL	$1.89 - $3.86 $7,637 - $15,598	-4,041 Reduced 36.75%	6,956 $23,000
Q1 2023 Dec 18, 2023	BUY	$1.97 - $3.58 $21,664 - $39,369	10,997 New	10,997 $25,000
Q1 2023 May 09, 2023	BUY	$1.97 - $3.58 $21,664 - $39,369	10,997 New	10,997 $26,000

121

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.